Abstract
Metabolic Syndrome: Pipeline Analysis and U.S. Market Forecast is a thorough
evaluation of marketed therapies and drugs in development for obesity,
dyslipidemia, type 2 diabetes, and hypertension.
Metabolic Syndrome is a cluster of risk factors for atherosclerotic disease
and type 2 diabetes mellitus comprising obesity, insulin resistance,
hypertension, and dyslipidemia. The eligible treatment population in the U.S.
for these four conditions is currently 40 million patients and will nearly
double over the next 15 years, bringing unprecedented social and economic
impacts.
Specifically, this report:
- Reveals the latest findings about the interactions among widely prevalent
lifestyle factors such as poor nutrition, being overweight, and sedentary
lifestyle, and how they contribute to insulin resistance, dyslipidemia, and
high blood pressure.
- Assesses the strengths and weaknesses of 13 R&D pipelines focused on
metabolic syndrome, comparing products and mechanisms in each disease
category against one another and against the gold standard.
- Presents 15-year forecasts of sales in the U.S. of marketed and
investigative therapies for each of the four disorders, taking into account
unmet medical need, changes in epidemiology, patent expirations, and
competitive drug launches.
- Spotlights the most promising drugs and early-stage mechanisms of action
and the likely timeframe for their launch.
Decision makers in early-stage development are waking up to the need for
solid market intelligence about competitor projects and the commercial potential
of products in development. Forecasts are taking a central role in the
commercial assessment of early-stage drug therapies, where they can serve as the
repository of a companys latest thinking on both commercial and clinical
questions. Through a reliable, early-stage forecast and an assessment of
products in development, Metabolic Syndrome: Pipeline Analysis and U.S. Market
Forecast provides R&D managers with the clinical data, the analytical tools,
and the market intelligence they need to make informed decisions about
individual projects and portfolios. | 
View Cart
